Discussion
cognitive decline, dementia
CVD, HYPERTENSION
Identifying baseline characteristics that project a higher magnitude of benefit within a clinical trial population is challenging yet important to advance personalized medicine.Hypertension is an important modifiable risk factor for CVD and dementia.Overall, greater cognitive benefit was observed with intensive BP treatment in patients at greater risk of cognitive decline at baseline (